Table 4.

References to the various elements in HTA reports for onasemnogene abeparvovec (Zolgensma)

Item	NICE	ICER	CADTH	SMC	AIFA	HAS	G-BA
Severe disease	Yes	Yes	Yes	Yes	Yes	Yes	N/A
Value to caregivers	Yes	Yes	Yes	Yes	N/A	Yes	N/A
Insurance value	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Scientific spillovers	Yes	N/A	N/A	N/A	N/A	N/A	N/A
Lack of alternatives	No	No	No	No	No	No	N/A
Substantial improvement in life expectancy	Yes	Yes	Yes	Yes	Yes	Yes	N/A
Discounting	Yes	Yes	N/A	Yes	Yes	Yes	N/A
Different discount rates employed	Yes	Yes	N/A	Yes	Yes	Yes	N/A
Uncertainty	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Alternative payment models explored	No	N/A	No	No	Yes	N/A	N/A

N/A = information not available in the HTA report or supporting material